Interestingly, recent studies have identified a prognostic potential for this gene in the context of endometrial cancer [39], lung adenocarcinoma [40] and acute myeloid leukaemia [41], where DNA methylation levels are increased in its promoter region, and a decrease in the expression of GYPC is associated with a worse prognosis in these patients. This evidence concerns the gene GYPC and acute myeloid leukemia.